Fairmount Funds Management LLC

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
West Conshohocken, PA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Fairmount Funds Management LLC

Form 4 holding Director

Cogent Biosciences, Inc.

Security class
Series A Convertible Preferred Stock
Shares / value
39,414
Estimated value
$598,636,320
Report date
31 Mar 2026
Price
$8880.00
Ownership
Fairmount Healthcare Fund II LP
Underlying class
Common Stock
Underlying amount
16,853,500
Form 4 holding Director, 10%+ Owner

Galecto, Inc.

Security class
Common Stock
Shares / value
5,809,000
Estimated value
$126,752,380
Report date
09 Feb 2026
Price
$21.82
Ownership
By Fairmount Healthcare Fund II L.P.
Form 4 holding Director, 10%+ Owner

Galecto, Inc.

Security class
Common Stock
Shares / value
2,904,000
Estimated value
$63,365,280
Report date
09 Feb 2026
Price
$21.82
Ownership
By Fairmount Healthcare Co-Invest V L.P.
Form 4 holding Director, 10%+ Owner

CRESCENT BIOPHARMA, INC.

Security class
Pre-Funded Warrant (Right to Buy)
Shares / value
2,294,037
Estimated value
$33,261,242
Report date
16 Jul 2026
Price
$14.50
Ownership
By Fairmount Healthcare Fund II L.P.
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Director

Dianthus Therapeutics, Inc. /DE/

Security class
Common Stock
Shares / value
2,700,691
Estimated value
$32,408,292
Report date
27 Sep 2024
Price
$12.00
Ownership
By Fairmount Healthcare Fund II L.P.
Form 4 holding Director, 10%+ Owner

Jade Biosciences, Inc.

Security class
Common Stock
Shares / value
2,655,817
Estimated value
$22,924,746
Report date
06 Oct 2025
Price
$8.63
Ownership
By Fairmount Healthcare Co-Invest IV L.P.
Form 4 holding Director

Dianthus Therapeutics, Inc. /DE/

Security class
Pre-Funded Warrants (Right to Buy)
Shares / value
832,333
Estimated value
$9,987,164
Report date
22 Jan 2024
Price
$12.00
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Jade Biosciences, Inc.

Security class
Pre-Funded Warrant (Right to Buy)
Shares / value
855,047
Estimated value
$7,815,044
Report date
06 Oct 2025
Price
$9.14
Ownership
By Fairmount Healthcare Fund II L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Oruka Therapeutics, Inc.

Security class
Series A Non-Voting Convertible Preferred Stock
Shares / value
0
Estimated value
$0
Report date
19 Nov 2024
Price
$23000.00
Ownership
By Fairmount Healthcare Fund II L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Spyre Therapeutics, Inc.

Security class
Series A Preferred Stock
Shares / value
346,045
Estimated value
Report date
23 Jun 2026
Price
Ownership
Fairmount Healthcare Fund II LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Oruka Therapeutics, Inc.

Security class
Series B Preferred Stock
Shares / value
94,497
Estimated value
Report date
01 Jul 2026
Price
Ownership
By Fairmount Healthcare Fund II L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Damora Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
37,313
Estimated value
Report date
23 Mar 2026
Price
Ownership
By: Peter Harwin
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Jade Biosciences, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
34,843
Estimated value
Report date
09 Jun 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Spyre Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
25,000
Estimated value
Report date
29 May 2025
Price
Ownership
By Peter Harwin
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Zenas BioPharma, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
18,500
Estimated value
Report date
10 Jun 2025
Price
Ownership
By Tomas Kiselak
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

CRESCENT BIOPHARMA, INC.

Security class
Stock Option (Right to Buy)
Shares / value
11,050
Estimated value
Report date
02 Jun 2026
Price
Ownership
By: Peter Harwin
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Director

Dianthus Therapeutics, Inc. /DE/

Security class
Stock Option (Right to Buy)
Shares / value
11,000
Estimated value
Report date
23 May 2024
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Oruka Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
9,136
Estimated value
Report date
02 Jun 2026
Price
Ownership
By: Peter Harwin
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Spyre Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
8,026
Estimated value
Report date
27 May 2026
Price
Ownership
By Tomas Kiselak
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Galecto, Inc.

Security class
Series C Preferred Stock
Shares / value
1,148
Estimated value
Report date
09 Feb 2026
Price
Ownership
By Fairmount Healthcare Fund II L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Galecto, Inc.

Security class
Series C Preferred Stock
Shares / value
574
Estimated value
Report date
09 Feb 2026
Price
Ownership
By Fairmount Healthcare Co-Invest V L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Spyre Therapeutics, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
23 Jun 2026
Price
Ownership
Fairmount Healthcare Fund II LP
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Fairmount Funds Management LLC

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .